By Peter G. Traber, M.D. on March 17, 2016 We often talk about how Galectin Therapeutics’ proprietary compound, GR-MD-02, is protected by a strong intellectual property portfolio. I thought it...
Read More
By Peter G. Traber, M.D. on February 22, 2016 Everyone has had the experience of having their blood pressure taken and knows the importance of a normal reading for good...
Read More
By Peter G. Traber, M.D. on February 3, 2016 Are you one of the nearly 40% of Americans classified as obese or are you overweight and inexorably headed towards obesity? ...
Read More
By Galectin Therapeutics. on January 7, 2016 The many accomplishments at Galectin Therapeutics during 2015 ranged from incremental progress touching every aspect of our business to significant advancements with GR-MD-02. Importantly,...
Read More
Written by Peter G. Traber, M.D. on September 9, 2015 An important question in drug development, and the subject of U.S. Food and Drug Administration (FDA) regulations, is whether a...
Read More
Written by Peter G. Traber, M.D. on September 2, 2015 In late June 2015, Galectin Therapeutics initiated a Phase 2 clinical trial (the NASH-CX trial) to evaluate the ability of...
Read More Successful Phase 1 Clinical Trial Supports Phase 2 Clinical Development Program
1 Comments , in Article
Written by Peter G. Traber, M.D. on August 24, 2015 Galectin Therapeutics completed and reported on a successful Phase 1 clinical trial in NASH patients with advanced fibrosis. In a...
Read More
Written by Peter G. Traber, M.D. on August 17, 2015 Galectin Therapeutics is developing a drug called GR-MD-02 which binds to and inhibits the galectin-3 protein which is important in...
Read More The Potential for Treatment of Liver Fibrosis With Galectin’s Drug Candidate GR-MD-02
0 Comments , in Article
Written by Peter G. Traber, M.D. on July 31, 2015 Liver fibrosis is scar formation in the liver which, when it reaches a large amount of scar tissue (called cirrhosis),...
Read More
Written by Peter G. Traber, M.D. on July 31, 2015 During the normal course of conducting business in a public company like Galectin Therapeutics, as the CEO and Chief Medical...
Read More